Adjusting Bioequivalence Acceptance Ranges: A Regulatory and Statistical Guide

Introduction: The Standard BE Limits and Their Significance

Bioequivalence (BE) assessments rely on comparing key pharmacokinetic parameters like AUC (Area Under the Curve) and C_max (maximum plasma concentration) between a test and reference formulation. The default regulatory acceptance limits for the 90% confidence interval (CI) of the geometric mean ratio (GMR) of these parameters is 80.00% to 125.00%. These limits ensure that any pharmacokinetic differences are not clinically meaningful.

However, these standard limits may be too stringent for highly variable drugs (HVDs), where within-subject variability inflates the CI. Regulatory agencies recognize this challenge and allow for acceptance range adjustments under specific conditions. Understanding how and when these adjustments apply is critical for study success.

What Triggers an Adjustment of BE Acceptance Ranges?

The primary trigger for range adjustment is high variability in the reference product, typically when the within-subject coefficient of variation (CV%) exceeds 30% for either AUC or C_max. This variability makes it statistically difficult to meet the 80–125% CI range even when the test and reference are essentially equivalent.

In such cases, regulators permit scaled or widened limits to accommodate the inherent variability, as long as robust statistical controls are in place to avoid compromising patient safety or efficacy.

Regulatory Perspectives on BE Range Adjustments

FDA and EMA both allow range adjustments but differ slightly in scope:

• FDA: Accepts Reference-Scaled Average Bioequivalence (RSABE) with limits based on the variability of the reference product. Applies to both AUC and C_max.
• EMA: Allows scaling only for C_max, not AUC, and imposes strict design and statistical requirements.

For example, in RSABE, if CV% of the reference exceeds 30%, BE limits may be expanded up to approximately 69.84%–143.19%, depending on the calculated within-subject variance (σ²_WR).

Mathematical Framework for RSABE

The statistical model used for RSABE includes a test of the scaled BE limit and a constraint on the point estimate:

θ = (ln(GMR))² - θ * σ²_WR ≤ ln(1.25)²
Where:
GMR = Geometric Mean Ratio
σ²_WR = within-subject variance for reference
θ = regulatory constant (usually 0.76)
      

If this condition is met, and the point estimate of the GMR lies within 80.00%–125.00%, the product can be declared bioequivalent.

Dummy Table: BE Acceptance Limits Based on CV%

Software Tools and Statistical Modeling

Implementation of range adjustments requires statistical software like SAS (PROC MIXED), Phoenix WinNonlin, or R (nlme, lme4 packages). The model must include fixed effects (sequence, period, formulation) and random effects (subject nested within sequence).

Regulators may request full model output, including residual diagnostics and justification for the chosen method. It is crucial to define all criteria in the protocol and statistical analysis plan (SAP).

Real-World Example: Adjusted Limits in a Generic Antidepressant Trial

A BE study on a generic venlafaxine extended-release product showed:

• CV% for C_max = 41%
• Unscaled 90% CI: 76.9% – 132.8%

The study failed under standard limits but passed under RSABE with scaled limits of 72.5% – 137.5%, with GMR = 101.8% within 80–125%. Regulatory approval was granted after detailed justification using FDA’s RSABE framework.

Reference: See similar cases on ClinicalTrials.gov using “replicate design” and “high variability” as keywords.

Important Considerations in Adjusting BE Ranges

• Point Estimate Constraint: Always required to be within 80.00%–125.00%
• Replicate Design: Mandatory for applying RSABE
• Clear Justification: Protocol must outline CV%, model, and intended analysis approach
• Sensitivity Analysis: Recommended if borderline results observed

Conclusion: Range Adjustments — A Regulatory-Compliant Path to BE

Bioequivalence range adjustments offer a scientifically justified and regulatory-accepted path for demonstrating BE in highly variable drugs. By leveraging replicate study designs and applying appropriate statistical models, sponsors can overcome challenges posed by high intra-subject variability. However, transparency in protocol, strict adherence to statistical assumptions, and precise documentation are essential to achieve regulatory approval.